more

AbbVie (ABBV)

(Delayed Data from NYSE)

$175.55 USD

-1.19 (-0.67%)

Updated Jan 14, 2025 04:00 PM ET

After-Market: $175.72 +0.17 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.35%
2	Buy	18.11%
3	Hold	9.74%
4	Sell	5.34%
5	Strong Sell	2.80%
S&P	500	11.41%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum D VGM

Industry Rank:

Bottom 23% (186 out of 242)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Research for ABBV

Annual Key Company Metrics
Quarterly Key Company Metrics

Revenue - Line of Business Segments	YR Estimate	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Net Revenue: Mavyret [$M]		--	1,430	1,541	1,710	1,830
Net Revenue: Hematologic Oncology...		--	5,915	6,577	5,408	5,314
Net Revenue: Immunology: Total [$...		--	26,136	28,924	25,284	22,153
Net Revenue: Neuroscience: Total ...		--	7,717	6,528	5,927	3,496
Net Revenue: Other Neuroscience: ...		--	276	475	685	539
Net Revenue: Other Aesthetics: To...		--	1,234	1,290	1,466	760
Net Revenue: Aesthetics: Total [$...		--	5,294	5,333	5,233	2,590
Net Revenue: Other Eye Care: Tota...		--	803	1,175	1,169	693
Net Revenue: Eye Care: Total [$M]		--	2,415	2,701	3,567	2,184
Net Revenue: Juvederm Collection:...		--	1,378	1,428	1,535	718
Net Revenue: Botox Therapeutic: T...		--	2,991	2,719	2,451	1,387
Net Revenue: Alphagan/Combigan: T...		--	272	346	529	326
Net Revenue: Lumigan/Ganfort [$M]		--	432	514	579	378
Net Revenue: Restasis: Total [$M]		--	436	666	1,290	787
Net Revenue: Linzess/Constella: T...		--	1,108	1,035	1,038	667
Net Revenue: Other Key Products: ...		--	3,806	3,854	5,489	--
Net Revenue: Eye Care: Ozurdex: T...		--	472	--	--	--
Net Revenue: Epkinly: Total [$M]	--	--	31	--	--	--
Net Revenue: Creon [$M]		--	1,268	--	1,191	1,114
Net Revenue: Humira [$M]		--	14,404	19,769	20,694	19,832
Net Revenue: Immunology: Skyrizi:...		--	7,763	5,165	2,939	1,590
Net Revenue: Rinvoq: Total [$M]		--	3,969	2,522	1,651	731
Net Revenue: Imbruvica [$M]		--	3,596	4,568	5,408	5,314
Net Revenue: Venclexta [$M]		--	2,288	2,009	1,820	1,337
Net Revenue: Botox Cosmetic: Tota...		--	2,682	2,615	2,232	1,112
Net Revenue: Vraylar: Total [$M]		--	2,759	2,038	1,728	951
Net Revenue: Duodopa [$M]		--	468	458	511	494
Net Revenue: Ubrelvy: Total [$M]		--	815	680	552	125
Net Revenue: Qulipta: Total [$M]		--	408	158	--	--
Revenue - Geographic Segments	YR Estimate	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Net Revenue: Mavyret: US [$M]		--	659	755	754	785
Net Revenue: Mavyret: Internation...		--	771	786	956	1,045
Net Revenue: Immunology: Total US...		--	21,737	24,897	21,087	18,150
Net Revenue: Immunology: Total In...		--	4,399	4,027	4,197	4,003
Net Revenue: Hematologic Oncology...		--	3,778	4,435	5,255	5,109
Net Revenue: Hematologic Oncology...		--	2,137	2,142	1,973	1,542
Net Revenue: Neuroscience: U.S [$...		--	6,790	5,681	5,061	2,862
Net Revenue: Neuroscience: Intern...		--	927	847	866	634
Net Revenue: Other Neuroscience: ...		--	254	456	667	528
Net Revenue: Other Neuroscience: ...		--	22	19	18	11
Net Revenue: Other Aesthetics: U....		--	1,060	1,122	1,268	666
Net Revenue: Other Aesthetics: In...		--	174	168	198	94
Net Revenue: Aesthetics: U.S [$M]		--	3,249	3,324	3,350	1,671
Net Revenue: Aesthetics: Internat...		--	2,045	2,009	1,883	919
Net Revenue: Other Eye Care: U.S ...		--	433	538	523	305
Net Revenue: Other Eye Care: Inte...		--	370	637	646	388
Net Revenue: Eye Care: U.S [$M]		--	1,252	1,603	2,403	1,448
Net Revenue: Eye Care: Internatio...		--	1,163	1,098	1,164	736
Net Revenue: Ubrelvy: U.S [$M]		--	803	680	552	125
Net Revenue: Ubrelvy: Internation...		--	12	--	0	0
Net Revenue: Botox Cosmetic: US [...		--	1,670	1,654	1,424	687
Net Revenue: Botox Cosmetic: Inte...		--	1,012	961	808	425
Net Revenue: Juvederm Collection:...		--	519	548	658	318
Net Revenue: Juvederm Collection:...		--	859	880	877	400
Net Revenue: Botox Therapeutic: U...		--	2,476	2,255	2,012	1,155
Net Revenue: Botox Therapeutic: I...		--	515	464	439	232
Net Revenue: Alphagan/Combigan: U...		--	121	202	373	223
Net Revenue: Alphagan/Combigan: I...		--	151	144	156	103
Net Revenue: Lumigan/Ganfort: US ...		--	173	242	273	165
Net Revenue: Lumigan/Ganfort: Int...		--	259	272	306	213
Net Revenue: Restasis: US [$M]		--	382	621	1,234	755
Net Revenue: Restasis: Internatio...		--	54	45	56	32
Net Revenue: Vraylar: US [$M]		--	2,755	2,037	1,728	951
Net Revenue: Vraylar: Internation...		--	4	1	0	0
Net Revenue: Linzess/Constella: U...		--	1,073	1,003	1,006	649
Net Revenue: Linzess/Constella: I...		--	35	32	32	18
Net Revenue: Other Key Products: ...		--	3,000	3,036	4,322	--
Net Revenue: Other Key Products: ...		--	806	818	1,167	--
Net Revenue: Eye Care: Ozurdex: U...		--	143	--	--	--
Net Revenue: Eye Care: Ozurdex: R...		--	329	--	--	--
Net Revenue: Qulipta: U.S. [$M]	--	--	405	158	--	--
Net Revenue: Qulipta: Internation...	--	--	3	--	--	--
Net Revenue: Epkinly: U.S [$M]	--	--	26	--	--	--
Net Revenue: Epkinly: Internation...	--	--	5	--	--	--
Geographic Revenues: United State...		--	41,883	45,713	43,510	34,879
Net Revenue: Creon: US [$M]		--	1,268	1,278	1,191	1,114
Net Revenue: Duodopa: Internation...		--	371	363	409	391
Net Revenue: Duodopa: US [$M]		--	97	95	102	103
Geographic Revenues: Internationa...		--	12,435	12,341	--	10,925
Net Revenue: Humira: US [$M]		--	12,160	18,619	17,330	16,112
Net Revenue: Humira: Internationa...		--	2,244	2,618	3,364	3,720
Net Revenue: Immunology: Skyrizi:...		--	6,753	4,484	2,486	1,385
Net Revenue: Immunology: Skyrizi:...		--	1,010	681	453	205
Net Revenue: Rinvoq: US [$M]		--	2,824	1,794	1,271	653
Net Revenue: Rinvoq: Internationa...		--	1,145	728	380	78
Net Revenue: Imbruvica: US [$M]		--	2,665	3,426	4,321	4,305
Net Revenue: Imbruvica: Internati...		--	931	1,142	1,087	1,009
Net Revenue: Venclexta: US [$M]		--	1,087	1,009	934	804
Net Revenue: Venclexta: Internati...		--	1,201	1,000	886	533

Revenue - Line of Business Segments	Qtr Estimate	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023
Net Revenue: Mavyret [$M]		302	369	349	309	370
Net Revenue: Hematologic Oncology...		1,687	1,634	1,543	1,509	1,512
Net Revenue: Immunology: Total [$...		7,046	6,971	5,371	6,953	6,783
Net Revenue: Neuroscience: Total ...		2,363	2,162	1,965	2,094	2,043
Net Revenue: Other Neuroscience: ...		84	80	74	66	61
Net Revenue: Other Aesthetics: To...		310	318	319	319	298
Net Revenue: Aesthetics: Total [$...		1,239	1,390	1,249	1,371	1,239
Net Revenue: Other Eye Care: Tota...		207	225	200	181	207
Net Revenue: Eye Care: Total [$M]		525	533	538	585	605
Net Revenue: Juvederm Collection:...		258	343	297	334	321
Net Revenue: Botox Therapeutic: T...		848	814	748	776	748
Net Revenue: Alphagan/Combigan: T...		62	49	59	66	70
Net Revenue: Lumigan/Ganfort [$M]		116	103	91	92	91
Net Revenue: Restasis: Total [$M]		21	32	57	128	117
Net Revenue: Linzess/Constella: T...		234	221	266	283	288
Net Revenue: Other Key Products: ...		874	962	900	968	963
Net Revenue: Eye Care: Ozurdex: T...		119	124	131	118	120
Net Revenue: Epkinly: Total [$M]		43	36	36	17	14
Net Revenue: Creon [$M]		338	372	285	376	305
Net Revenue: Humira [$M]		2,227	2,814	2,270	3,304	3,547
Net Revenue: Immunology: Skyrizi:...		3,205	2,727	2,008	2,394	2,126
Net Revenue: Rinvoq: Total [$M]		1,614	1,430	1,093	1,255	1,110
Net Revenue: Imbruvica [$M]		828	833	838	903	908
Net Revenue: Venclexta [$M]		677	637	614	589	590
Net Revenue: Botox Cosmetic: Tota...		671	729	633	718	620
Net Revenue: Vraylar: Total [$M]		875	774	694	789	751
Net Revenue: Duodopa [$M]		111	113	115	115	118
Net Revenue: Ubrelvy: Total [$M]		269	231	203	234	233
Net Revenue: Qulipta: Total [$M]		176	150	131	114	132
Revenue - Geographic Segments	Qtr Estimate	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023
Net Revenue: Mavyret: US [$M]		147	167	144	128	167
Net Revenue: Mavyret: Internation...		155	202	205	181	203
Net Revenue: Immunology: Total US...		5,713	5,717	4,152	5,774	5,696
Net Revenue: Immunology: Total In...		1,333	1,254	1,219	1,179	1,087
Net Revenue: Hematologic Oncology...		1,113	1,037	967	971	973
Net Revenue: Hematologic Oncology...		574	597	576	538	539
Net Revenue: Neuroscience: U.S [$...		2,088	1,895	1,714	1,861	1,817
Net Revenue: Neuroscience: Intern...		275	267	251	233	226
Net Revenue: Other Neuroscience: ...		54	57	61	59	55
Net Revenue: Other Neuroscience: ...		30	23	13	7	6
Net Revenue: Other Aesthetics: U....		272	275	281	275	255
Net Revenue: Other Aesthetics: In...		38	43	38	44	43
Net Revenue: Aesthetics: U.S [$M]		791	863	776	884	759
Net Revenue: Aesthetics: Internat...		448	527	473	487	480
Net Revenue: Other Eye Care: U.S ...		115	131	105	99	114
Net Revenue: Other Eye Care: Inte...		92	94	95	82	93
Net Revenue: Eye Care: U.S [$M]		240	239	227	314	310
Net Revenue: Eye Care: Internatio...		285	294	311	271	295
Net Revenue: Ubrelvy: U.S [$M]		261	227	197	229	230
Net Revenue: Ubrelvy: Internation...		8	4	6	5	3
Net Revenue: Botox Cosmetic: US [...		414	450	389	453	388
Net Revenue: Botox Cosmetic: Inte...		257	279	244	265	232
Net Revenue: Juvederm Collection:...		105	138	106	156	116
Net Revenue: Juvederm Collection:...		153	205	191	178	205
Net Revenue: Botox Therapeutic: U...		708	669	611	649	626
Net Revenue: Botox Therapeutic: I...		140	145	137	127	122
Net Revenue: Alphagan/Combigan: U...		26	13	15	31	30
Net Revenue: Alphagan/Combigan: I...		36	36	44	35	40
Net Revenue: Lumigan/Ganfort: US ...		58	42	29	31	28
Net Revenue: Lumigan/Ganfort: Int...		58	61	62	61	63
Net Revenue: Restasis: US [$M]		8	18	44	117	104
Net Revenue: Restasis: Internatio...		13	14	13	11	13
Net Revenue: Vraylar: US [$M]		873	773	692	788	750
Net Revenue: Vraylar: Internation...		2	1	2	1	1
Net Revenue: Linzess/Constella: U...		225	211	257	274	279
Net Revenue: Linzess/Constella: I...		9	10	9	9	9
Net Revenue: Other Key Products: ...		710	750	686	778	751
Net Revenue: Other Key Products: ...		164	212	214	190	212
Net Revenue: Eye Care: Ozurdex: U...		33	35	34	36	34
Net Revenue: Eye Care: Ozurdex: R...		86	89	97	82	86
Net Revenue: Qulipta: U.S. [$M]		168	146	128	113	131
Net Revenue: Qulipta: Internation...		8	4	3	1	1
Net Revenue: Oncology: Elahere: U...		139	128	128	--	--
Net Revenue: Epkinly: U.S [$M]		16	14	14	12	14
Net Revenue: Epkinly: Internation...		27	22	22	5	--
Net Revenue: Oncology: Elahere: T...		139	128	128	--	--
Geographic Revenues: United State...		11,148	11,106	9,041	11,110	10,852
Net Revenue: Creon: US [$M]		338	372	285	376	305
Net Revenue: Duodopa: Internation...		87	90	90	92	93
Net Revenue: Duodopa: US [$M]		24	23	25	23	25
Geographic Revenues: Internationa...		3,312	3,356	3,269	3,191	3,075
Net Revenue: Humira: US [$M]		1,765	2,360	1,771	2,740	3,020
Net Revenue: Humira: Internationa...		462	454	499	564	527
Net Revenue: Immunology: Skyrizi:...		2,778	2,340	1,656	2,105	1,875
Net Revenue: Immunology: Skyrizi:...		427	387	352	289	251
Net Revenue: Rinvoq: US [$M]		1,170	1,017	725	929	801
Net Revenue: Rinvoq: Internationa...		444	413	368	326	309
Net Revenue: Imbruvica: US [$M]		618	595	610	683	678
Net Revenue: Imbruvica: Internati...		210	238	228	220	230
Net Revenue: Venclexta: US [$M]		340	300	281	276	281
Net Revenue: Venclexta: Internati...		337	337	333	313	309

Member Sign In

Member Sign In

Services Overview

Investor Services

Other Services

Trading Services

Innovators